Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Pentamidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 2/20 | 0.77 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.77 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.77 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.77 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.77 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.77 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.77 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.77 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.77 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.77 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.77 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.77 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.77 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.77 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.77 |
| ▸ | PLAU | P00749 | 1/20 | 0.77 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.77 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.77 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.77 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentamidine SCHEMBL27531881 | 1.00 | PRMT1 (0.77) | PRMT1F2ST14TMPRSS2PLAU | |
| Pentamidine SCHEMBL9701269 | 0.93 | PRMT1 (0.83) | PRMT1F2ST14TMPRSS2PLAU | |
| Pentamidine SCHEMBL28765996 | 0.92 | ALDH1A1 (0.76) | PRMT1F2ST14TMPRSS2PLAU | |
| Pentamidine SCHEMBL28351858 | 0.88 | PRMT1 (0.69) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL9547468 | 0.88 | LTB4R (0.61) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL9547435 | 0.88 | LTB4R (0.61) | PRMT1F2ST14TMPRSS2PLAU | |
| Pentamidine SCHEMBL3329 | 0.88 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| Heptamidine SCHEMBL14599630 | 0.88 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL14599639 | 0.88 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| Hexamidine SCHEMBL144738 | 0.88 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210378992-A1 | METHODS FOR TREATING A SUBTYPE OF SMALL CELL LUNG CANCER | AURANSA INC. | 2021-12-09 | — | — | US | claimed |
| WO-2020082037-A1 | METHODS FOR TREATING A SUBTYPE OF SMALL CELL LUNG CANCER | AURANSA INC. (US) | 2020-04-23 | — | — | WO | claimed |
| US-6693125-B2 | ADMINISTERING THE DRUGS PENTAMIDINE, AND ONE OF ALBENDAZOLE, MEBENDAZOLE, OR OXIBENDAZOLE; SYNERGISTIC | COMBINATORX INCORPORATED | 2004-02-17 | — | — | US | claimed |
| CN-120131572-A | Loratadine tablet and preparation process thereof | 天方药业有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20210378992-A1 | METHODS FOR TREATING A SUBTYPE OF SMALL CELL LUNG CANCER | AURANSA INC. | 2021-12-09 | — | — | US | disclosed |
| WO-2020082037-A1 | METHODS FOR TREATING A SUBTYPE OF SMALL CELL LUNG CANCER | AURANSA INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20180296530-A1 | METHOD FOR TREATING ATOPIC DERMATITIS | CHIANG BOR LUEN (TW) | 2018-10-18 | — | — | US | disclosed |
| US-20130108660-A1 | ANTI-TRYPANOSOME THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-02 | — | — | US | disclosed |
| CN-102834381-A | Pyridoxine derivatives for the inhibition of HIV integrase | TAIMED BIOLOG INC | 2012-12-19 | — | — | CN | disclosed |
| US-20120276131-A1 | ANTI-TRYPANOSOMIASIS VACCINES AND DIAGNOSTICS | UNIVERSITE BORDEAUX SEGALEN (FR) | 2012-11-01 | — | — | US | disclosed |
| WO-2011042565-A2 | ANTIPROTOZOAL ACTIVITY | INSTITUUT VOOR TROPISCHE GENEESKUNDE (BE) | 2011-04-14 | — | — | WO | disclosed |
| WO-2006053162-A1 | PTPASE INHIBITORS AND T-CELL ACTIVATORS FOR TREATING CANCER | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050215629-A1 | PTPase inhibitors and methods of using the same | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-09-29 | — | — | US | disclosed |
| US-20030161893-A1 | PTPase inhibitors and methods of using the same | CLEVELAND CLINIC FOUNDATION, THE | 2003-08-28 | — | — | US | disclosed |
| WO-2003063788-A2 | PTPase INHIBITORS AND METHODS OF USING THE SAME | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20020150964-A1 | Peptides for the activation of the immune system in humans and animals | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | 2002-10-17 | — | — | US | disclosed |
| US-6440690-B1 | ADMINISTERING CATIONIC AMPHIPATHIC PEPTIDE (DERMASEPTIN FOR EXAMPLE) IN GIVEN DOSAGE | Mor, Amram (IL) | 2002-08-27 | — | — | US | disclosed |
| EP-0600915-B1 | BOX-BASED COMPOSITION FOR TREATING HIV (HUMAN IMMUNODEFICIENCY VIRUS) INFECTION | UNIV NICE SOPHIA ANTIPOLIS (FR) | 1997-11-12 | — | — | EP | disclosed |
| EP-0600915-A1 | BOX-BASED COMPOSITION FOR TREATING HIV (HUMAN IMMUNODEFICIENCY VIRUS) INFECTION | UNIVERSITE DE NICE-SOPHIA ANTIPOLIS (FR) | 1994-06-15 | — | — | EP | disclosed |
| WO-1993000916-A1 | BOX-BASED COMPOSITION FOR TREATING HIV (HUMAN IMMUNODEFICIENCY VIRUS) INFECTION | UNIVERSITE DE NICE SOPHIA ANTIPOLIS (FR) | 1993-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210378992-A1 | METHODS FOR TREATING A SUBTYPE OF SMALL CELL LUNG CANCER | RNMT, SLC17A5, TSG101 | F2 4882/4885ADRA2A 2525/4885DRD1 4027/4885 |
| US-20180296530-A1 | METHOD FOR TREATING ATOPIC DERMATITIS | MTNR1A, MTNR1B, TSLP | F2 3034/4885ADRA2A 453/4885DRD1 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.